About Myricx Bio
Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
Sectors & Market Categories
Company Details
Corporate & Operational Profile
Primary Industry
Biotech & Healthcare
Funding Stage
Series-A
Global Headquarters
London, United Kingdom
Year Founded
2019
Team Size
11–50 employees
Tracked Since
Nov 8, 2026
Web & Domain Identity
Official Website
myricxbio.com
Domain Registered Date
Undisclosed
Social & Network Presence
X / Twitter Profile
Not linked
LinkedIn Corporate
Company Profile
Company Milestones & Timeline
- Capital Raise
Raised $120,000,000 · Series-A
Backed by Abingworth
- Milestone
Company founded
London, United Kingdom
Investors & Backers
Abingworth
Lead
Brandon Capital
British Patient Capital
Cancer Research Horizons
Eli Lilly
Novo Holdings
Sofinnova Partners
Funding History
Series-A equity
· Jul 8, 2024
Round backers: Abingworth
$120,000,000 startupintros.com
Founders & Leadership
Andrew Bell
Founder
Work email & phone locked
Unlock →
Ed Tate
Founder
Work email & phone locked
Unlock →
Francesco Falciani
Head of Bioinformatics
Work email & phone locked
Unlock →
Grant Hawthorne
CFO
Work email & phone locked
Unlock →
Jonathon Marks-Bluth
Vice President of Business Development
Work email & phone locked
Unlock →
Penny Fatato
Vice President of Global Clinical Operations
Work email & phone locked
Unlock →
Richard Rutter
Head of Biology
Work email & phone locked
Unlock →
Roberto Solari
Founder
Work email & phone locked
Unlock →
Robin Carr
Chief Technology Officer
Work email & phone locked
Unlock →
Zahid Bashir
Chief Medical Officer
Work email & phone locked
Unlock →
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allTesorai
tesorai.com
Seed Nov 2026
Commit Biologics
commitbio.com
Seed Aarhus · Nov 2026
Human Biome
human-biome.com
Series-A Warsaw · Nov 2026
MedInTech
medintech.co.kr
Series-B Seoul · Nov 2026
Ace Padel
acepadel.com
Seed Bradenton, United States · Nov 2026
Mentix
mentix.world
Pre-Seed London, United Kingdom · Nov 2026